Holen Sie sich die Stockscreener-App
67.96
2.04%
1.36
Handel nachbörslich:
67.96
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$66.60
Offen:
$67.75
24-Stunden-Volumen:
5.41M
Relative Volume:
0.97
Marktkapitalisierung:
$210.75B
Einnahmen:
$51.21B
Nettoeinkommen (Verlust:
$6.50B
KGV:
32.59
EPS:
2.085
Netto-Cashflow:
$6.76B
1W Leistung:
+3.96%
1M Leistung:
+3.99%
6M Leistung:
-13.66%
1J Leistung:
+2.13%
1-Tages-Spanne:
$67.59
$68.38
1-Wochen-Bereich:
$65.03
$68.38
52-Wochen-Spanne:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
67.96 | 210.75B | 51.21B | 6.50B | 6.76B | 2.085 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN - GlobeNewswire Inc.
ASTRAZENECA ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming DeadlinesAZN - PR Newswire
AstraZeneca PLC ADR rises Tuesday, outperforms market - MarketWatch
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients - Yahoo Finance UK
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer - BioPharma Dive
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca PLC (AZN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
2025-01-21 | AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca PLC (NASDAQ:AZN) Holdings Lifted by Brookmont Capital Management - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by ZWJ Investment Counsel Inc. - MarketBeat
Investors who lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about pending Class ActionAZN - GuruFocus.com
AZN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN - Markets Insider
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer - Yahoo Finance
US Dato-DXd Approval Relief For AstraZeneca and Daiichi Sankyo - News & Insights
2025-01-20 | Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN | NDAQ:AZN | Press Release - Stockhouse Publishing
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse Publishing
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN - Stockhouse Publishing
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineAZN - PR Newswire
AstraZeneca gets first US approval for cancer treatment Datroway - ShareCast
AstraZeneca Plc Datroway approved in the US for metastatic breast cancer - DirectorsTalk Interviews
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Oak Ridge Investments LLC - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC - GlobeNewswire
Professional Advisory Services Inc. Raises Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Position Cut by Boston Common Asset Management LLC - MarketBeat
AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector (NASDAQ:AZN) - Seeking Alpha
Procyon Advisors LLC Has $2.21 Million Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
23,847 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Empirical Asset Management LLC - MarketBeat
US FDA approves AstraZeneca's drug for breast cancer - Reuters.com
AstraZeneca, Daiichi Win FDA Approval for Breast Cancer Drug - Bloomberg
2025-01-17 | Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline - Benzinga
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs - BioPharma Dive
AstraZeneca rises Friday, still underperforms market - MarketWatch
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma - Benzinga
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or - GlobeNewswire
AstraZeneca changes management of its China unit (AZN:NASDAQ) - Seeking Alpha
Faruqi & Faruqi Reminds AstraZeneca Investors of the - GlobeNewswire
AstraZeneca lymphoma drug gets expanded U.S. approval (AZN) - Seeking Alpha
AstraZeneca overhauls management of its China division, FT reports -January 17, 2025 at 09:12 am EST - Marketscreener.com
AstraZeneca overhauls management of its scandal-hit China division - Financial Times
Channel Wealth LLC Purchases 23,711 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca’s Calquence Wins FDA Approval for Mantle Cell Lymphoma - TipRanks
AstraZeneca's Calquence gains FDA nod for 1L MCL treatment - Investing.com
Ritholtz Wealth Management Cuts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
FDA grants full approval for AstraZeneca's Calquence - The Pharma Letter
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth - Pharmaceutical Technology
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
AstraZeneca drug for rare blood cancer gets US regulatory green light - Proactive Investors USA
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):